Dakik H A, Kleiman N S, Farmer J A, He Z X, Wendt J A, Pratt C M, Verani M S, Mahmarian J J
Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Circulation. 1998 Nov 10;98(19):2017-23. doi: 10.1161/01.cir.98.19.2017.
Patients who have inducible ischemia after acute myocardial infarction (AMI) generally undergo coronary angiography with the intent to revascularize. Whether this approach is superior to intensive treatment with anti-ischemic medications is unknown.
We performed a prospective, randomized pilot study comparing intensive medical therapy with coronary angioplasty (PTCA) for suppression of myocardial ischemia in 44 stable survivors of AMI. Myocardial ischemia was quantified with adenosine 201Tl tomography (SPECT) performed 4.5+/-2.9 days after AMI. All patients at baseline had a large total (>/=20%) and ischemic (>/=10%) left ventricular perfusion defect size (PDS). SPECT was repeated at 43+/-26 days after therapy was optimized. The total stress-induced PDS was comparably reduced with medical therapy (from 38+/-13% to 26+/-16%; P<0.0001) and PTCA (from 35+/-12% to 20+/-16%; P<0.0001). The reduction in ischemic PDS was also similar (P=NS) in both groups. Cardiac events occurred in 7 of 44 patients over 12+/-5 months. Patients who remained clinically stable had a greater reduction in ischemic PDS (-13+/-9%) than those who had a recurrent cardiac event (-5+/-7%; P<0.02). Event-free survival was superior in the 24 patients who had a significant (>/=9%) reduction in PDS (96%) compared with those who did not (65%; P=0.009).
In this small pilot study, intensive medical therapy and PTCA were comparable at suppressing ischemia in stable patients after AMI. Sequential imaging with adenosine SPECT can track changes in PDS after anti-ischemic therapies and thereby predict subsequent outcome. Corroboration of these preliminary findings in a larger cardiac-event trial is warranted.
急性心肌梗死(AMI)后出现可诱导性缺血的患者通常会接受冠状动脉造影,目的是进行血管重建。这种方法是否优于使用抗缺血药物的强化治疗尚不清楚。
我们进行了一项前瞻性随机试验研究,比较强化药物治疗与冠状动脉血管成形术(PTCA)对44例AMI稳定存活者心肌缺血的抑制作用。在AMI后4.5±2.9天,采用腺苷201Tl断层扫描(SPECT)对心肌缺血进行定量分析。所有患者基线时左心室灌注缺损大小(PDS)均较大,总缺损(≥20%)和缺血性缺损(≥10%)。在治疗优化后43±26天重复进行SPECT检查。药物治疗(从38±13%降至26±16%;P<0.0001)和PTCA(从35±12%降至20±16%;P<0.0001)使总应激诱导的PDS得到了相当程度的降低。两组缺血性PDS的降低也相似(P=无显著性差异)。44例患者在12±5个月内有7例发生心脏事件。临床保持稳定的患者缺血性PDS的降低幅度(-13±9%)大于发生心脏事件复发的患者(-5±7%;P<0.02)。PDS显著降低(≥9%)的24例患者的无事件生存率(96%)高于未显著降低的患者(65%;P=0.009)。
在这项小型试验研究中,强化药物治疗和PTCA在抑制AMI后稳定患者的缺血方面效果相当。腺苷SPECT序贯成像可追踪抗缺血治疗后PDS的变化,从而预测后续结果。有必要在更大规模的心脏事件试验中对这些初步发现进行验证。